Read This First
This page is not built on clinical evidence, because none exists for this compound. It is built on the FDA's July 2026 evaluation, the regulatory record and peptide chemistry. What KPV does in animals is covered on the library entry; this page is about what is in the vial, and about the gap between the product the advisory committee voted on and the products people buy.
KPV is a tripeptide with no approved product anywhere, no human study by any route, and, since July 2026, an advisory committee recommendation for compounding as a topical cream. The market sells it as an injectable, an oral capsule and a nasal spray, none of which is the product that was recommended.1
Legal Status
Where Does KPV Stand?
Approved nowhere. It has no marketing authorisation, no USP monograph, is not a component of an approved drug, and is not recognised by the European Medicines Agency or the European or Japanese pharmacopoeias.1
In the United States it was placed in the FDA's Category 2 of nominated compounding substances in September 2023, with the shortest safety entry on the list: the agency "has not identified any human exposure data on drug products containing KPV administered via any route of administration" and "lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans." As of April 2026 it appears among substances nominated but withdrawn.2
What Did the July 2026 Vote Change?
Nothing yet, and less than the marketing suggests when it does.
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend KPV free base and acetate for the 503A bulks list for wound healing and inflammatory conditions, against the FDA's recommendation.3 The nomination that was voted on proposed "cream and gel, 0.1% for topical administration."1
The recommendation is advisory. The bulks list can only be changed by rulemaking, the FDA has not begun one, and until it does no pharmacy in the United States has a lawful basis on which to compound KPV in any form. If the FDA eventually acts on the vote, a topical cream would become compoundable on prescription. Injectable, oral and nasal KPV would not, because they were never before the committee.
A seller citing the July vote for an injectable is citing a recommendation for a different product, by a different route, that the FDA has not adopted.
Product Identity
What Is Being Sold?
The FDA's own survey of the market: compounded products containing KPV "appear to be offered online in the United States as single and multiple-peptide injectable, oral, topical, and nasal spray drug products, for use in conditions such as inflammation, inflammatory bowel diseases, wound healing, nerve damage, stroke, gut health, and psoriasis."1 It found no evidence of compounded KPV in the published literature or in outsourcing facility reports, so whatever is being dispensed is not being reported.
The multi-peptide products deserve a note. KPV is commonly blended with BPC-157 for "gut repair," and both were before the committee on the same day; BPC-157 was recommended for ulcerative colitis, KPV for wounds and skin. No study has tested the combination, and a certificate for a blend must report each component separately to mean anything.
What Makes a Tripeptide Hard to Verify?
Less than a long peptide, and that is worth saying. Three residues leave little room for deletion sequences, and synthesis is straightforward. The FDA's characterisation concerns were correspondingly narrow: certificates it found in the public domain had "no information on impurity limits/testing results," no aggregation data and no microbial testing; naming conventions were inconsistent; and the water solubility of 0.7 mg/mL raised a formulation question for the proposed cream that the nomination did not answer.1
For an injectable, that solubility figure matters differently. A product labelled at a concentration well above 0.7 mg/mL in water is either using a co-solvent or a salt form the label does not mention, or contains less dissolved peptide than it claims.
The Permeation Problem
An in vitro study in human cadaver skin found that KPV "does not permeate well through skin." The FDA drew both conclusions from that: low permeability "could limit the systemic toxicity" of a topical product, and "could also limit the potential effectiveness" because the peptide may never reach the living epidermis.1 A topical KPV cream may therefore be the safest product in this market and also the one least likely to do anything. An injectable removes the first property along with the second.
Purity Testing Versus Identity Testing
| Test | Question it answers | Question it cannot answer |
|---|---|---|
| HPLC purity | What proportion of the sample is one substance | Whether that substance is Lys-Pro-Val or a related sequence such as KdPT |
| Mass spectrometry identity | Whether the mass matches KPV, about 342 daltons | How much of the sample it represents |
| Endotoxin assay | Whether bacterial cell-wall fragments are present | Identity or content; this is the test the FDA found missing from public certificates |
| Sterility | Whether viable organisms are present | Anything about the peptide; essential for an injectable, and unreported |
Certificates of Analysis
What a Certificate Is
A laboratory report on one batch. Read it for the laboratory's independence from the seller, the lot number and whether it matches the vial, the date, the substance named including free base or acetate, and which tests were actually run. For KPV specifically, look for endotoxin and microbial results, since the FDA found certificates in circulation without them.1
What It Cannot Establish
That the vial in hand came from the batch tested. Its value rests on a chain of custody the buyer cannot inspect. A certificate is a PDF, and nothing about the format prevents reuse or fabrication; the FDA has documented fabricated labels on gray-market peptide products.4
"Research Use Only"
Does the Label Change Anything?
No. It is a liability position adopted by the seller, not a regulatory category. The FDA has held in warning letters that the disclaimer does not survive product copy establishing human use.5 A page describing gut healing, an anti-inflammatory protocol and a July 2026 committee vote, followed by a line that the vial is not for human consumption, has supplied the agency's argument.
Storage and Handling
What Is Known
No manufacturer-validated storage specification exists for any product a consumer can buy. A tripeptide of natural amino acids is chemically robust as a dry powder; the ordinary rules apply to solutions. Oral KPV faces a specific problem that the gut-delivery literature exists to solve: it is digested. The 2008 mouse work delivered it in drinking water and relied on PepT1 uptake in an inflamed colon; the nanoparticle and hydrogel work since exists because free peptide does not reliably arrive.67 A capsule of plain KPV is the formulation those researchers moved away from.
Multi-Dose Vials
The FDA's guidance for compounded injectables is to discard a multi-dose vial within 28 days of first use regardless of what remains, and to use a new sterile needle and syringe for every dose.4
Signs to Stop Rather Than Proceed
Injectable product with no sterility or endotoxin result on its certificate
A stated concentration in water well above 0.7 mg/mL with no explanation
Injection-site reactions that grow with successive doses
A blend certificate that reports a single purity figure for two peptides
Community Language
KPV
Lysine-proline-valine, the C-terminal tripeptide of alpha-MSH. The subject of this page.
KdPT
Lysine-D-proline-threonine, a related tripeptide from interleukin-1β that went into European clinical development. A different molecule; its data do not transfer.
BPC/KPV, gut stack
A blend of BPC-157 and KPV. Untested as a combination. Both were before the committee in July 2026 for different uses.
Category 2
The FDA's interim classification for nominated compounding substances that may present significant safety risks. KPV was placed there in 2023 and is now listed as nominated but withdrawn.2
Certificate of analysis
A laboratory report on one batch. It describes the batch tested, not necessarily the vial received.
Related ONPEPS Coverage
KPV library entry: the animal data, the absent human data and the July 2026 vote
KPV cost and access: what an advisory vote does and does not buy
FDA peptide news July 2026: the votes, the dissent and what happens next
Sources
US Food and Drug Administration. KPV-related bulk drug substances (KPV (free base) and KPV acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 23 July 2026. Docket FDA-2025-N-6895. fda.gov
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for KPV. Content current as of 22 April 2026. fda.gov
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 8 to 6 vote with one abstention on KPV. onpeps.com
US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug Alerts and Statements. Cited for the agency's general guidance on multi-dose vials and fabricated labels. fda.gov
US Food and Drug Administration. Warning Letter: Gram Peptides. MARCS-CMS 721806, 31 March 2026. fda.gov
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. Open access. pubmed.ncbi.nlm.nih.gov/18061177
Zhao Y, Xue P, Lin G, Tong M, Yang J, Zhang Y, et al. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomater. 2022;143:233-252. Paywalled. pubmed.ncbi.nlm.nih.gov/35245681
Not Medical Advice
KPV holds no marketing authorisation for human use in any jurisdiction and has never been studied in a human being. If you are already using a product obtained outside a pharmacy, the route back to oversight is a clinician who knows what you have taken.
Regulatory sources verified 16 September 2026. The FDA had not acted on the July 2026 advisory recommendation as of that date, and the compounding record changes frequently. Re-verify before relying on any statement here.